

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	20721YCA
First Inventor or Application Identifier	
Title	TYROSINE KINASE INHIBITORS
Express Mail Label No.	

EV321986454US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

- | | |
|--|---|
| 1. <input checked="" type="checkbox"/> Fee Transmittal Form
<i>(Submit an original, and a duplicate for fee processing)</i> | 6. Nucleotide and/or Amino Acid Sequence Submission
<i>(if applicable, all necessary)</i> |
| 2. <input checked="" type="checkbox"/> Specification [Total Pages 169] | a. <input type="checkbox"/> Computer Readable Form (CRF) |
| 3. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets] | b. <input type="checkbox"/> Specification Sequence Listing on:
i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or
ii. <input type="checkbox"/> paper |
| 4. Oath or Declaration | c. <input type="checkbox"/> Statements verifying identity of above copies |
| a. <input type="checkbox"/> Newly executed (original or copy) | 7. <input type="checkbox"/> Assignment papers (cover sheet & document(s)) |
| b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d))
<i>(for continuation/divisional with Box 14 completed)</i> | 8. <input type="checkbox"/> 37 CFR 3.73(b) Statement
<i>(when there is an assignee)</i> |
| i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u>

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b). | 9. <input type="checkbox"/> Information Disclosure Statement |
| 5. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 | 10. <input checked="" type="checkbox"/> Preliminary Amendment |
| 14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: | 11. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503)
<i>(Should be specifically itemized)</i> |
| <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) | 12. <input type="checkbox"/> Certified Copy of Priority Document(s)
<i>(if foreign priority is claimed)</i> |
| Prior application information: Examiner D. R. Rao | 13. <input checked="" type="checkbox"/> Other: <u>Associate Power of Attorney</u> |

U.S. PTO
10/677687
31108 100203

ACCOMPANYING APPLICATION PARTS

- | | |
|--|--|
| 7. <input type="checkbox"/> Assignment papers (cover sheet & document(s)) | <input type="checkbox"/> Power of Attorney |
| 8. <input type="checkbox"/> 37 CFR 3.73(b) Statement
<i>(when there is an assignee)</i> | <input type="checkbox"/> Copies of IDS Citations |
| 9. <input type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> IDS Citations |
| 10. <input checked="" type="checkbox"/> Preliminary Amendment | |
| 11. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503)
<i>(Should be specifically itemized)</i> | |
| 12. <input type="checkbox"/> Certified Copy of Priority Document(s)
<i>(if foreign priority is claimed)</i> | |
| 13. <input checked="" type="checkbox"/> Other: <u>Associate Power of Attorney</u> | |

14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation Divisional Continuation-in-part (CIP) of prior application No. 09 /990,473


Group/Art Unit: 1624

Prior application information: Examiner D. R. Rao
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

15. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number	Customer No. 000210		
---	---------------------	--	--

NAME	Matthew A. Leff			
ADDRESS	Merck & Co., Inc., P. O. Box 2000 - Patent Dept., RY60-30			
CITY	Rahway	STATE	NJ	ZIP CODE
COUNTRY	USA	TELEPHONE	732-594-1404	FAX

Name	Matthew A. Leff	Registration No. (Attorney/Agent)	50,149
Signature			Date


10/2/2003

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT October 2, 2003

EXPRESS MAIL NO. EV321986454US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

MAILED BY  DATE October 2, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents,
P.O. Box 1450
Alexandria, Virginia 22313-1450

Prior Application:

Examiner	D. R. Rao
Art Unit	1624

Sir: This is a request for filing a Continuation Divisional application, under 37 C.F.R. 1.53(b), of pending application Serial No. 09/990,473 filed on

11/21/01 of Mark T. Bilodeau et al.

(DATE)

(INVENTOR)

for TYROSINE KINASE INHIBITORS

(TITLE OF INVENTION)

1. The enclosed comprises a copy of prior application Serial No. 09/990,473, as filed on 11/21/01. The entire disclosure of this prior application is hereby incorporated by reference.

2. The filing fee is calculated below:

CLAIMS AS FILED IN THE PRIOR APPLICATION, LESS ANY CLAIMS CANCELED BY AMENDMENT BELOW

FOR	NUMBER FILED	NUMBER EXTRA	RATE	Fee
Total Claims	35	-	\$18	\$270
Independent Claims	6	-	\$86	\$258
*Multiple Dependent Claims		3	\$290	
Basic Fee (minimum amount required)				\$770
				\$1,298 Total Fee

* Add this fee if application contains any multiple dependent claims, regardless of number.

3. The Commissioner is hereby authorized to charge any fees which may be required or to credit any overpayment to Account No. 13-2755.

4. Amend the specification by inserting before the first line the sentence:
-- This is a continuation, division of application Serial No. _____, filed _____.
5. Cancel in this application original claims: _____.
6. Preliminary amendment enclosed.
7. Information Disclosure Statement/PTO-1449 enclosed.
- 8a. Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.
- 8b. New formal drawings are enclosed.
- 9a. Priority of application Serial No. _____, filed _____, in _____ is claimed under 35 U.S.C. 119.
- 9b. (COUNTRY) The certified copy of the priority application has been filed in prior application Serial No. _____, filed _____.
10. The prior application is assigned to Merck & Co., Inc. _____.
11. The undersigned attorney or agent has:
- Power in the prior application as originally filed.
 - Associate power, copy enclosed.

Respectfully,

By: Matthew A. Left

Agent _____ for Applicant(s)

Registration No. 50,149

Telephone: (732) 594-1404

Address: Merck & Co., Inc.
Patent Department
P.O. Box 2000 - RY60-30
Rahway, N.J. 07065-0907

Date: 10/2/2003

EXPRESS MAIL CERTIFICATE	
DATE OF DEPOSIT	10/2/2003
EXPRESS MAIL NO. EV321986454US	
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.	
MAILED BY	For Scheppele
DATE	10/2/2003

IN DUPLICATE